Regulatory Innovation for a More Personalized Era of Medicine

Key Takeaways

• Regulatory innovation is becoming essential as personalized medicines move beyond biomarker-defined populations toward individualized therapies designed for very small patient groups or even one or two patients.

• The FDA’s emerging frameworks for individualized therapies, rare-disease evidence, and small-population cell and gene therapy trials reflect a shift toward fit-for-purpose evidence rather than reduced standards.

• Individualized ASOs illustrate how clinical evidence, CMC strategy, product characterization, and manufacturing controls must be integrated early in development.

• Patient-specific manufacturing models are making regulatory strategy and manufacturing strategy increasingly inseparable for personalized medicines.

• Global regulators, including the FDA, EMA, MHRA, Health Canada, and PMDA, are developing different mechanisms to support advanced therapies, rare diseases, and products that do not fit traditional development models.

Personalized medicine has moved beyond the broad concept of matching a therapy class to a biomarker-defined population. In some areas of development, the product itself may be designed for a very small group of patients, a single family, or even one or two prospectively identified individuals. Individualized antisense oligonucleotides (ASOs), patient-specific cell and gene therapies, genome-editing approaches, and other highly tailored modalities are forcing regulators to address development scenarios that were not well captured by traditional models for evidence generation, manufacturing oversight, or clinical trial design.

The challenge is not simply that these medicines are scientifically complex. It is that the normal tools of drug development can become difficult to apply when the relevant population is extremely small, when the biological rationale is specific to a known genetic abnormality, or when each product is linked closely to an individual patient or manufacturing run. In these situations, randomized controlled trials may not be feasible, manufacturing may not resemble conventional batch production, and the evidentiary package may need to rely on a carefully integrated understanding of mechanism, natural history, product performance, and clinical observation.¹

Regulators are not responding by abandoning standards. The more important development is that agencies are building new ways to apply existing expectations to therapies that do not fit older assumptions. The emerging direction is toward earlier scientific dialogue, more explicit use of fit-for-purpose evidence, flexible approaches to small-population trial design, and manufacturing frameworks that account for individualized or advanced production models. For developers, the message is clear: personalization does not remove the need for rigor, but it does change where rigor must be concentrated.

The most direct example of this shift is the FDA’s draft guidance on the plausible mechanism framework for individualized therapies that target specific genetic conditions with a known biological cause. The guidance is aimed at therapies designed around a defined causal abnormality and addresses how evidence of effectiveness and safety may be generated in settings where more conventional development paths are constrained by population size.²

The importance of this framework lies in the type of problem it recognizes. For some ultra-rare genetic diseases, the relevant patient population may be too small to support a conventional randomized trial. In other cases, a treatment may be designed for a particular molecular abnormality that appears in only a very limited number of people. The FDA’s public discussion of the framework explicitly connects this challenge to individualized therapies for ultra-rare diseases and to situations in which randomized controlled trials are not feasible because patient populations are small.¹

Under this model, the evidentiary question becomes more mechanistic and integrative. The agency describes considerations that include identifying the disease-causing abnormality, showing that the therapy targets the root cause or a proximate biological pathway, relying on well-characterized natural history information, and confirming that the target has been successfully drugged or edited.¹ That structure does not eliminate uncertainty, but it provides a way to evaluate whether a product’s biological rationale, product activity, and clinical evidence are aligned.

The framework is especially relevant for genome-editing and RNA-based therapies, including ASOs, but the broader concepts may apply to other individualized therapies.^1,2 This is significant because it suggests that the regulatory question is not limited to one modality. It is a recurring problem across technologies that can be rationally designed around a known disease mechanism but may never have enough patients for the type of trial program used in more common diseases.

A careful reading also shows that the framework is not a shortcut around evidence. It is a proposal for organizing evidence when the available development path is constrained. That distinction matters for the field. Biopharma companies developing individualized medicines will need to demonstrate that the disease biology is understood, that the therapeutic intervention is plausibly connected to that biology, that the product can be manufactured to appropriate quality standards, and that clinical safety and effectiveness can be assessed using the data available for the patient population in question.

Individualized ASOs provide a useful early example of how regulators are beginning to address therapies designed for extremely small numbers of patients. The FDA has issued clinical recommendations for investigational individualized ASO drug products intended for severely debilitating or life-threatening genetic diseases.³ The FDA has also issued chemistry, manufacturing, and controls recommendations for individualized ASO investigational new drug (IND) submissions, making clear that the regulatory challenge extends well beyond clinical trial design.⁴

This product class illustrates why individualized medicine can strain the traditional development model. The FDA’s chemistry, manufacturing, and controls (CMC) guidance addresses ASO products for unique genetic variants where only a small number of individuals are prospectively identified, typically one or two.⁴ In that setting, the development program cannot be built around broad enrollment, large comparative data sets, or commercial-scale manufacturing assumptions. The regulatory task is instead to determine how much information is needed, what type of information is most relevant, and how the total package can support responsible clinical use.

The ASO example also demonstrates that individualized does not mean informal. Even when a product is designed for one or two known individuals, CMC information remains central to regulatory review. Manufacturing controls, product characterization, and quality expectations are not secondary issues; they are part of how regulators assess whether an individualized therapeutic candidate can be administered responsibly.⁴

This is an important lesson for other personalized modalities. As more therapies are designed around patient-specific or variant-specific biology, sponsors will need to plan evidence generation and manufacturing strategy together. A compelling biological rationale may be necessary, but it will not be sufficient if the product cannot be characterized, controlled, and documented in a manner that supports clinical investigation.

The broader regulatory direction is toward fit-for-purpose evidence, not a lower standard for approval. The FDA’s Rare Disease Evidence Principles initiative is useful in this regard because it is designed for rare diseases with very small patient populations, significant unmet medical need, and a known genetic defect that is the major driver of the disease’s pathophysiology.⁵ At the same time, FDA states that drugs reviewed under this process will continue to be reviewed under the statutory marketing approval standard for safety and efficacy.

That distinction should guide how developers think about personalized medicine regulation. The question is not whether evidence is still required. It is what kind of evidence can reasonably establish safety and effectiveness when patient numbers are very limited. This places greater importance on the quality of the mechanistic rationale, the relevance of biomarkers or endpoints, the strength of natural-history data, and the ability to interpret clinical outcomes in context.

Natural-history studies are likely to play a central role in this environment. The FDA’s rare-disease natural-history guidance is intended to inform the design and implementation of natural-history studies that can support development of safe and effective drugs and biological products for rare diseases.⁶ For ultra-small populations, understanding the expected course of disease may be essential for interpreting whether an observed change is meaningful, whether a patient’s trajectory differs from expectation, and whether the timing or magnitude of response supports the therapeutic rationale.

This also reinforces the value of early planning. Natural-history data cannot be assembled retroactively with the same confidence as data collected with a clear development purpose. Endpoint strategy, data standards, follow-up duration, and clinical assessments all need to be considered before a pivotal evidentiary question emerges. For personalized medicines, where each patient’s data can carry unusual weight, the quality of that data becomes even more consequential.

The same logic applies to the evidence principles that the FDA is developing for rare-disease programs. Greater flexibility places more responsibility on sponsors to make the evidence coherent. Regulators may be open to alternative evidence structures, but those structures must still support a persuasive assessment of benefit and risk.

Small patient populations require trial designs that extract the greatest possible value from limited data. The FDA’s draft guidance on innovative clinical trial designs for cellular and gene therapy products in small populations directly addresses sponsors planning trials for products intended to treat diseases or conditions affecting small populations, generally those meeting the definition of a rare disease or condition under the Food, Drug, and Cosmetic Act.⁷

The relevance to personalized medicine is straightforward. Many individualized or highly targeted products will be developed in settings where every eligible patient matters. Enrollment may be slow, disease heterogeneity may be high, and conventional control groups may be difficult or impossible to construct. In these circumstances, trial design must be considered not only as a statistical exercise but also as a strategy for preserving interpretability.

For cellular and gene therapies, this issue can be particularly acute. Products may be developed for diseases with a known genetic basis, and the intended intervention may be closely tied to that disease mechanism. Where development populations are small, the evidentiary strategy must connect the product’s intended biological effect with clinical outcomes that can be measured credibly in the available patients.⁷

This does not mean that all small-population programs will follow the same model. The sources reviewed here support the broader principle that development plans need to be tailored to the product, disease, population, and evidentiary constraints. They do not support a single universal design solution. That reality may be frustrating for sponsors looking for a template, but it is consistent with the nature of personalized medicines. When the product and population are highly specific, the evidence strategy must also be specific.

Early regulatory interaction becomes especially important in this context. A trial design that is scientifically elegant but misaligned with regulatory expectations can place a small-population program at serious risk. Conversely, early discussion can help sponsors understand what uncertainties matter most, what types of data may be most useful, and how the trial can be designed to preserve the interpretability of each patient’s contribution.

Personalized medicines also put manufacturing at the center of regulatory innovation. The individualized ASO CMC guidance makes this clear for one product class, but the principle is broader: when products are made for extremely small groups of patients, or when manufacturing is closely linked to patient-specific material, quality expectations must be adapted without being weakened.⁴

The CMC package for an individualized product must address the same fundamental question as any other product: whether the therapy can be made with sufficient quality, consistency, and control to support its intended use. What changes is the operating model. A conventional development program may generate extensive process history before broad clinical use. An individualized product may need to rely on platform knowledge, prior experience, analytical controls, and a focused product-specific package.

Advanced manufacturing may help address part of this challenge. The FDA’s Advanced Manufacturing Technologies Designation Program is intended to facilitate the development of drugs manufactured using designated advanced manufacturing technologies.⁸ The agency emphasizes that advanced manufacturing technologies can improve manufacturing reliability and robustness and may benefit patients by enhancing product quality, reducing development time, or increasing or maintaining the supply of certain important drugs.

For personalized medicines, those goals are highly relevant. Patient-specific and ultra-small-batch production can place pressure on speed, documentation, analytical testing, and release processes. Manufacturing systems that support reliability, process understanding, and reproducible quality may become essential to making individualized development operationally feasible. Regulatory innovation in this area is therefore not only about review timelines or clinical evidence; it is also about whether manufacturing models can support safe and timely patient access.

This has direct implications for manufacturing partners. Contract development and manufacturing organizations (CDMOs) supporting personalized medicines will need to understand that flexibility cannot come at the expense of product characterization or control. Sponsors may need partners capable of working within small-batch or individualized workflows while still maintaining the documentation, analytical rigor, and quality systems expected for regulated products. The more individualized the therapy, the more closely manufacturing strategy, regulatory strategy, and clinical strategy must be integrated.

The European regulatory framework provides another view of how agencies are responding to advanced and personalized therapies. The European Medicines Agency defines advanced therapy medicinal products as medicines for human use that are based on genes, tissues, or cells. These therapies include gene therapies, somatic cell therapies, and tissue-engineered products, and they are governed in the European Union by Regulation (EC) No 1394/2007.⁹

The regulation itself is important because it recognizes that advanced therapies require specially tailored and harmonized rules because of their novelty, complexity, and technical specificity.¹⁰ This legal framing is directly relevant to personalized medicine. It acknowledges that certain therapeutic categories cannot be regulated effectively by simply applying older assumptions without modification.

The EU framework also includes a hospital exemption for certain advanced therapy medicinal products prepared on a non-routine basis according to specific quality standards, used within the same member state in a hospital, under the exclusive professional responsibility of a medical practitioner, and made to comply with an individual medical prescription for a custom-made product for an individual patient.¹¹ This exemption is sometimes discussed as a route for highly individualized therapies, but it is bounded by specific conditions, not an open exemption from oversight.

PRIME adds another layer to Europe’s approach. EMA describes PRIME as a scheme to support the development of medicines that target an unmet medical need and are not yet authorized in the EU.¹² The program is based on early dialogue with developers to optimize development plans and accelerate evaluation. For personalized medicines, the relevance is not that PRIME is specific to individualized products, but that it reflects a broader regulatory movement toward earlier, more structured engagement for products addressing serious unmet needs.

The EMA has also introduced additional PRIME tools following a pilot, including tools intended to strengthen scientific dialogue and preparation for marketing authorization submission.¹³ For developers of complex therapies, that kind of interaction can be particularly important. Questions about evidence, manufacturing, comparability, and patient selection often need to be addressed before late-stage development, not after the major program decisions have already been made.

The European experience therefore shows two complementary approaches: a product-category framework for advanced therapies and a development-support mechanism for promising medicines addressing unmet medical need. Together, they point toward a regulatory model that combines defined legal categories with earlier scientific engagement.

Other regulators are approaching the same pressures through different mechanisms. In the United Kingdom, the Innovative Licensing and Access Pathway is intended to accelerate time to patient access for transformative new medicines and drug-device combinations.¹⁴ The Innovation Passport serves as the entry point into the pathway, and UK materials indicate that ILAP can include advanced therapy medicinal products, medicines for rare diseases, and repurposed medicines.^14,15

The significance of ILAP for personalized medicine is its integrated model. The pathway is structured around collaborative working among the developer, the Medicines and Healthcare products Regulatory Agency, health technology assessment bodies, the National Health Service, and patients. That broader access-oriented structure matters because personalized medicines often raise questions that extend beyond regulatory approval. Evidence generation, patient identification, manufacturing logistics, reimbursement, and clinical adoption may all be interdependent.

Canada’s advanced therapeutic products framework addresses the problem from another angle. Health Canada states that ATPs can be drugs, devices, or combinations of both, and that they may face significant barriers under existing regulations.¹⁶ The agency describes a framework that allows regulatory requirements and oversight to be tested before regulations are changed.¹⁷ Health Canada also states that it is establishing a flexible, risk-based authorization framework based on Food and Drugs Act provisions from June 2019.¹⁸

This approach is particularly relevant to products that do not fit neatly into existing categories. Personalized medicines often blur lines among drug, device, biologic, procedure, software, and manufacturing system. A framework designed to tailor requirements based on the characteristics of the product category may be better suited to such technologies than a rigid classification model.

Japan’s approach to regenerative medical products offers another model. The Pharmaceuticals and Medical Devices Agency (PMDA) states that Japan’s PMD Act regulates commercialization of regenerative medical products, including certain manipulated cell products and gene therapy products.¹⁹ The PMDA also lists guidance for conditional and time-limited approval for regenerative medical products and subsequent efficacy-evaluation plans. The associated guidance supports the concept that conditional and time-limited approval may be available when safety is confirmed and efficacy can be predicted based on clinical trial results.²⁰

These approaches are not interchangeable, and they should not be treated as harmonized. They do, however, show that multiple regulators are trying to address similar pressures: scientific complexity, small populations, unmet need, patient-specific or advanced manufacturing, and the difficulty of applying conventional development models to emerging therapeutic categories.

Across these regulatory examples, several themes are emerging. The first is earlier engagement. The FDA’s plausible mechanism framework, the EMA’s PRIME scheme, the MHRA’s ILAP, and other initiatives all emphasize the value of dialogue before development programs become fixed. For personalized medicines, this is not a procedural preference. It is a practical necessity, because mistakes in evidence strategy, endpoint selection, manufacturing planning, or patient-selection criteria may be difficult to correct in ultra-small populations.

The second theme is fit-for-purpose evidence. Rare-disease and individualized-therapy programs often cannot rely on the same trial structures used in common diseases, but they still need evidence that supports safety and effectiveness. The regulatory direction is toward explaining what evidence may be persuasive in constrained settings, including mechanistic rationale, natural history, clinical observation, product characterization, and other supportive data.^2,5,6

The third theme is manufacturing control. Personalized medicine can make CMC more complex, not less important. Individualized ASOs, cell therapies, gene therapies, and other advanced modalities may require manufacturing models that are faster, smaller, more distributed, or more product-specific than conventional systems. Regulators are beginning to address those realities through CMC guidance, advanced manufacturing programs, and flexible oversight concepts, but the underlying expectation remains that products must be manufactured to appropriate quality standards.^4,8

The fourth theme is risk-based adaptation. Health Canada’s ATP framework, the EU’s ATMP rules, and the FDA’s small-population and individualized-therapy guidances all reflect the need to adapt requirements to the product and context rather than force every therapy through the same development mold.^7,10,17 That adaptation can support innovation, but it also places greater responsibility on sponsors to justify their development choices.

The fifth theme is that patient specificity changes the development timeline. For a conventional therapy, regulatory strategy may be staged over years of development. For an individualized therapy, the patient may already be known, the disease may be severe, and the window for intervention may be narrow. That context can intensify the need for early planning, rapid evidence synthesis, and manufacturing readiness.

For sponsors, the first implication is that regulatory strategy must begin with the biology. Personalized medicines are most likely to benefit from flexible evidence approaches when the disease mechanism, therapeutic target, and expected biological effect are clear. The FDA’s plausible mechanism framework places substantial weight on identifying the disease-causing abnormality and demonstrating that the therapy targets the root cause or a proximate biological pathway.¹ That means the mechanistic story cannot be treated as background science. It is part of the evidence strategy.

The second implication is that natural-history work and endpoint planning need to begin early. In ultra-small populations, weak or incomplete disease-course data can make clinical outcomes difficult to interpret. A single patient’s stabilization, improvement, or delayed progression may be meaningful only if the expected natural course is sufficiently understood. For developers, this makes natural-history planning a strategic asset, not merely an academic exercise.

The third implication is that CMC planning should not wait until the clinical concept is mature. For individualized medicines, the product’s manufacturability, analytical control strategy, release approach, and documentation model may determine whether the therapy can be delivered at all. The FDA’s individualized ASO CMC guidance and AMT Designation Program both point to the importance of manufacturing quality, reliability, and process understanding in advanced or individualized contexts.^4,8

This is where CDMOs can play an important role. CDMOs that support personalized medicines will need more than technical capacity. They will need the ability to operate within development models where patient need, regulatory evidence, analytical control, and manufacturing timelines are tightly connected. In some cases, sponsors may need support in translating a platform or product concept into a CMC package suitable for regulatory interaction. In others, they may need manufacturing systems that can handle small or individualized production while preserving traceability, quality, and documentation.

The fourth implication is that global development strategies need to account for regulatory differences. The FDA, the EMA, the MHRA, Health Canada, and the PMDA are all addressing advanced or personalized therapies, but through different mechanisms. A sponsor developing a personalized medicine cannot assume that a strategy aligned with one regulator will automatically satisfy another. The EU hospital exemption, PRIME, MHRA ILAP, Health Canada’s ATP framework, and Japan’s regenerative medical product pathway each reflect different legal structures and policy choices.^{11,12,14,17,19}

The final implication is that developers should be prepared to explain uncertainty rather than avoid it. Personalized medicines often involve limited data, urgent medical need, and complex biology. Regulatory innovation does not remove those uncertainties. It creates pathways for discussing them transparently, structuring evidence around them, and determining whether the totality of information supports development, investigation, or authorization.

Personalized medicines are pushing regulation toward a new logic. The older development model assumed that a product could usually be evaluated in a defined population large enough to support conventional clinical trials and manufactured through processes that could be repeated at scale. That model remains essential for many therapies, but it does not fit every individualized ASO, genome-editing product, patient-specific cell therapy, or ultra-rare disease program.

The regulatory response is still developing, but its main contours are visible. Agencies are creating frameworks for individualized therapies, clarifying expectations for products intended for one or two prospectively identified patients, supporting rare-disease evidence principles, encouraging small-population trial-design innovation, and building mechanisms for earlier dialogue and more tailored oversight.

The most important lesson for the field is that personalization increases the need for disciplined development. When there are fewer patients, each data point matters more. When the product is individualized, manufacturing control becomes more central. When the biological rationale is specific, the mechanistic evidence must be strong. When regulatory flexibility is available, sponsors need to show why their proposed approach is scientifically and clinically justified.

For patients with ultra-rare diseases, these innovations may help make development possible where conventional pathways would be impractical. For sponsors, they create both opportunity and responsibility. The opportunity is a more navigable regulatory environment for therapies designed around specific patients, variants, and biological mechanisms. The responsibility is to build evidence packages that are coherent, transparent, and rigorous enough to support regulatory decision-making in the absence of large traditional datasets.

Personalized medicine will not be advanced by regulatory flexibility alone. It will require a development model in which biology, clinical evidence, natural history, manufacturing, and regulatory engagement are planned as one integrated strategy. That is the emerging standard for therapies designed around the patient, and it is likely to define the next phase of innovation in ultra-rare and individualized medicine.

1. FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases. U.S. Food and Drug Administration. 23 Feb. 2026.

2. Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause: Draft Guidance. U.S. Food and Drug Administration. Feb. 2026.

3. IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry. U.S. Food and Drug Administration. Dec. 2021.

4. Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators: Draft Guidance for Industry. U.S. Food and Drug Administration. Dec. 2021.

5. “CDER/CBER Rare Disease Evidence Principles (RDEP).” U.S. Food and Drug Administration. 3 Sept. 2025.

6. Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry. U.S. Food and Drug Administration. Mar. 2019.

7. Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations: Draft Guidance for Industry. U.S. Food and Drug Administration. Sep. 2025.

8. Advanced Manufacturing Technologies Designation Program: Guidance for Industry. U.S. Food and Drug Administration. Dec. 2024.

9. Advanced Therapy Medicinal Products: Overview. European Medicines Agency. Accessed 5 Jun. 2026.

10. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union. L 324: 121–137 (2007).

11. “Hospital Exemption Provision.” In “Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and Amending Directive 2001/83/EC and Regulation (EC) No 726/2004.” Official Journal of the European Union. L 324: 121–137 (2007).

12. “PRIME: Priority Medicines.” European Medicines Agency. Accessed 5 Jun. 2026.

13. “New PRIME Tools to Accelerate Development of Medicines in the EU.” European Medicines Agency. 18 Mar. 2026.

14. “Innovative Licensing and Access Pathway (ILAP).” Medicines and Healthcare Products Regulatory Agency. 30 Jan. 2025.

15. The MHRA Innovative Licensing and Access Pathway Is Open for Business. Medicines and Healthcare Products Regulatory Agency. 1 Jan. 2021.

16. “Advanced Therapeutic Products (ATPs).” Health Canada. 14 Mar. 2025.

17. “A Framework for Regulating and Authorizing Advanced Therapeutic Products.” Health Canada. 14 Mar. 2025.

18. “Regulatory Innovation for Health Products: Enabling Advanced Therapeutic Products.” Health Canada. 17 June 2025.

19. “Regenerative Medical Products.” Pharmaceuticals and Medical Devices Agency. Accessed 5 Jun. 2026.

20. Guidance for Conditional and Time-Limited Approval for Regenerative Medical Products and the Development of Subsequent Efficacy Evaluation Plan. Ministry of Health, Labour and Welfare. 29 Mar. 2024.